Navigation Links
BD Announces Results for Third Fiscal Quarter
Date:7/24/2008

FRANKLIN LAKES, N.J., July 24 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of $1.868 billion for the third fiscal quarter ended June 30, 2008, representing an increase of 14.5 percent over the prior year period. This quarter's revenue growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for nearly 7 percentage points of the increase in quarterly revenues.

"We are pleased that all segments and regions, particularly Europe and Asia, contributed to solid revenue growth," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "We are also pleased with our operating results, which in part, have enabled us to raise our earnings guidance once again despite continued pressure from increasing raw material costs."

Analyses of Third Quarter and Nine-Month Periods of Fiscal Year 2008 and 2007 Earnings

Reported diluted earnings per share from continuing operations were $1.18 for the third quarter of fiscal 2008 and 95 cents for the third quarter of fiscal 2007. For the nine-month period ending June 30, 2008, reported diluted earnings per share from continuing operations were $3.34. For the nine-month period ending June 30, 2007, reported diluted earnings per share from continuing operations were $2.38.

The following analysis (Table 1) of diluted earnings per share from continuing operations for the three-month and nine-month periods ended June 30, 2008 and 2007, identifies the specified items that affect comparability of results between periods. As illustrated, diluted earnings per share from continuing operations of $1.18 for the third fiscal quarter of 2008 incr8,055 22.6

TOTAL $297,769 $257,648 15.6

TOTAL REVENUES

United States $798,275 $768,085 3.9

International 1,069,312 863,074 23.9

TOTAL $1,867,587 $1,631,159 14.5

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY SEGMENT AND GEOGRAPHIC AREA

(Unaudited; Amounts in thousands)

Nine Months Ended June 30,

2008 2007 % Change

BD MEDICAL

United States $1,197,689 $1,146,143 4.5

International 1,650,243 1,406,233 17.4

TOTAL $2,847,932 $2,552,376 11.6

BD DIAGNOSTICS

United States $840,695 $781,644 7.6

International 766,050 625,512 22.5

TOTAL $1,606,745 $1,407,156 14.2

BD BIOSCIENCES

United States $333,891 $314,942 6.0

International 531,711 434,133 22.5

TOTAL $865,602 $749,075 15.6

TOTAL REVENUES

United States $2,372,275 $2,242,729 5.8

International 2,948,004 2,465,878 19.6

TOTAL $5,320,279 $4,708,607 13.0

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended June 30,

(Unaudited; Amounts in thousands)

United States

2008 2007 % Change

BD MEDICAL

Medical Surgical

Systems $243,960 $238,360 2.3

Diabetes Care 102,663 92,116 11.4

Pharmaceutical

Systems 49,125 48,692 0.9

Ophthalmic Systems 6,170 6,378 (3.3)

TOTAL $401,918 $385,546 4.2

BD DIAGNOSTICS

Preanalytical

Systems $144,416 $139,572 3.5

Diagnostic Systems 135,702 133,374 1.7

TOTAL $280,118 $272,946 2.6

BD BIOSCIENCES

Cell Analysis (1) $80,186 $71,686 11.9

Discovery Labware 36,053 37,907 (4.9)

TOTAL $116,239 $109,593 6.1

TOTAL UNITED STATES $798,275 $768,085 3.9

(1) Cell Analysis consists of the Immunocytometry Systems and the

Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended June 30, (continued)

(Unaudited; Amounts in thousands)

International

% Change

FX FX

2008 2007 Reported Neutral Impact

BD MEDICAL

Medical Surgical

Systems $272,064 $233,835 16.3 6.1 10.2

Diabetes Care 97,298 82,754 17.6 4.8 12.8

Pharmaceutical

Systems 230,346 168,057 37.1 19.6 17.5

Ophthalmic Systems 14,770 11,794 25.2 12.6 12.6

TOTAL $614,478 $496,440 23.8 10.6 13.2

BD DIAGNOSTICS

Preanalytical

Systems $146,345 $121,761 20.2 7.5 12.7

Diagnostic Systems 126,959 96,818 31.1 18.4 12.7

TOTAL $273,304 $218,579 25.0 12.3 12.7

BD BIOSCIENCES

Cell Analysis (1) $141,889 $115,494 22.9 10.4 12.5

Discovery Labware 39,641 32,561 21.7 8.7 13.0

TOTAL $181,530 $148,055 22.6 10.0 12.6

TOTAL INTERNATIONAL $1,069,312 $863,074 23.9 10.9 13.0

(1) Cell Analysis consists of the Immunocytometry Systems and the

Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended June 30, (continued)

(Unaudited; Amounts in thousands)

Total

% Change

FX FX

2008 2007 Reported Neutral Impact

BD MEDICAL

Medical Surgical

Systems $516,024 $472,195 9.3 4.2 5.1

Diabetes Care 199,961 174,870 14.3 8.3 6.0

Pharmaceutical

Systems 279,471 216,749 28.9 15.4 13.5

Ophthalmic Systems 20,940 18,172 15.2 7.0 8.2

TOTAL $1,016,396 $881,986 15.2 7.8 7.4

BD DIAGNOSTICS

Preanalytical

Systems $290,761 $261,333 11.3 5.3 6.0

Diagnostic Systems 262,661 230,192 14.1 8.7 5.4

TOTAL $553,422 $491,525 12.6 6.9 5.7

BD BIOSCIENCES

Cell Analysis (1) $222,075 $187,180 18.6 10.9 7.7

Discovery Labware 75,694 70,468 7.4 1.4 6.0

TOTAL $297,769 $257,648 15.6 8.3 7.3

TOTAL REVENUES $1,867,587 $1,631,159 14.5 7.6 6.9

(1) Cell Analysis consists of the Immunocytometry Systems and the

Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Nine Months Ended June 30,

(Unaudited; Amounts in thousands)

United States

2008 2007 % Change

BD MEDICAL

Medical Surgical

Systems $729,152 $711,545 2.5

Diabetes Care 298,071 280,255 6.4

Pharmaceutical

Systems 151,882 135,961 11.7

Ophthalmic Systems 18,584 18,382 1.1

TOTAL $1,197,689 $1,146,143 4.5

BD DIAGNOSTICS

Preanalytical

Systems $428,391 $403,211 6.2

Diagnostic Systems 412,304 378,433 9.0

TOTAL $840,695 $781,644 7.6

BD BIOSCIENCES

Cell Analysis (1) $225,814 $205,237 10.0

Discovery Labware 108,077 109,705 (1.5)

TOTAL $333,891 $314,942 6.0

TOTAL UNITED STATES $2,372,275 $2,242,729 5.8

(1) Cell Analysis consists of the Immunocytometry Systems and the

Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Nine Months Ended June 30, (continued)

(Unaudited; Amounts in thousands)

International

% Change

2008 2007 Reported FX Neutral FX Impact

BD MEDICAL

Medical

Surgical

Systems $766,401 $675,741 13.4 3.7 9.7

Diabetes

Care 278,736 234,491 18.9 7.1 11.8

Pharmaceutical

Systems 563,969 462,540 21.9 8.3 13.6

Ophthalmic

Systems 41,137 33,461 22.9 11.6 11.3

TOTAL $1,650,243 $1,406,233 17.4 6.0 11.4

BD DIAGNOSTICS

Preanalytical

Systems $408,031 $342,941 19.0 7.5 11.5

Diagnostic

Systems 358,019 282,571 26.7 15.8 10.9

TOTAL $766,050 $625,512 22.5 11.3 11.2

BD BIOSCIENCES

Cell

Analysis(1) $421,095 $339,146 24.2 13.0 11.2

Discovery

Labware 110,616 94,987 16.5 5.4 11.1

TOTAL $531,711 $434,133 22.5 11.4 11.1

TOTAL

INTER-

NATIONAL $2,948,004 $2,465,878 19.6 8.3 11.3

(1) Cell Analysis consists of the Immunocytometry Systems and the

Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Nine Months Ended June 30, (continued)

(Unaudited; Amounts in thousands)

Total

% Change

2008 2007 Reported FX Neutral FX Impact

BD MEDICAL

Medical

Surgical

Systems $1,495,553 $1,387,286 7.8 3.1 4.7

Diabetes

Care 576,807 514,746 12.1 6.7 5.4

Pharmaceutical

Systems 715,851 598,501 19.6 9.0 10.6

Ophthalmic

Systems 59,721 51,843 15.2 7.9 7.3

TOTAL $2,847,932 $2,552,376 11.6 5.3 6.3

BD DIAGNOSTICS

Preanalytical

Systems $836,422 $746,152 12.1 6.8 5.3

Diagnostic

Systems 770,323 661,004 16.5 11.9 4.6

TOTAL $1,606,745 $1,407,156 14.2 9.2 5.0

BD BIOSCIENCES

Cell

Analysis(1) $646,909 $544,383 18.8 11.9 6.9

Discovery

Labware 218,693 204,692 6.8 1.7 5.1

TOTAL $865,602 $749,075 15.6 9.1 6.5

TOTAL

REVENUES $5,320,279 $4,708,607 13.0 7.1 5.9

(1) Cell Analysis consists of the Immunocytometry Systems and the

Pharmingen units that were previously reported separately.

eased by 20 percent over diluted earnings per share from continuing operations, excluding the specified item, of 98 cents for the third fiscal quarter of 2007. For the nine-month periods, diluted earnings per share from continuing operations of $3.34 for fiscal 2008 increased by 17 percent over comparable fiscal 2007 diluted earnings per share from continuing operations of $2.86, which exclude the specified items.

(Table 1) Three Months Ended June 30, Nine Months Ended June 30,

FY2008 FY2007 % Change FY2008 FY2007 % Change

Diluted EPS

from

Continuing

Operations: $1.18 $0.95 24% $3.34 $2.38 40%

Specified Items:

In-Process

Research and

Development

Charge - 0.03 (1) - 0.48 (2)

Diluted EPS from

Continuing

Operations

Excluding

Specified

Items: $1.18 $0.98 20% $3.34 $2.86 17%

(1) Represents the effect on diluted earnings per share from continuing

operations of the in-process research and development ("IPR&D") charge

recorded in the third quarter of fiscal 2007 related to the Plasso

Technology acquisition.

(2) Represents the effect on diluted earnings per share from continuing

operations of the IPR&D charges recorded in the third and first

quarters of fiscal 2007 related to the Plasso and TriPath

acquisitions, respectively.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.016 billion, representing an increase of 15 percent from the prior year period. Pharmaceutical Systems and Diabetes Care products led revenue growth in the segment. For the nine-month period ended June 30, 2008, the BD Medical segment reported 12 percent revenue growth.

In the BD Diagnostics segment, worldwide revenues for the quarter were $553 million, representing an increase of 13 percent from the prior year's quarter. Sales of safety-engineered devices, TriPath products and infectious disease testing systems contributed to revenue growth. For the nine-month period ended June 30, 2008, the BD Diagnostics segment reported 14 percent revenue growth.

In the BD Biosciences segment, worldwide revenues for the quarter were $298 million, representing an increase of 16 percent from the prior year's quarter. Demand for clinical and research instruments and reagents were the primary growth drivers. For the nine-month period ended June 30, 2008, the BD Biosciences segment reported 16 percent revenue growth.

Geographic Results

Third quarter revenues in the U.S. were $798 million, representing an increase of 4 percent over the prior year period. Revenues outside the U.S. were $1.069 billion, representing an increase of 24 percent over the prior year period, with approximately 13 percentage points of the increase resulting from the favorable impact of foreign currency translation.

For the nine-month period ended June 30, 2008, revenues in the U.S. were $2.372 billion, representing an increase of 6 percent over the prior year period. Revenues outside of the U.S. were $2.948 billion, representing an increase of 20 percent over the prior year period, with approximately 11 percentage points of the increase resulting from the favorable impact from foreign currency translation.

Fiscal 2008 Outlook for Full Year

The Company raised its guidance for full fiscal year 2008 diluted earnings per share from continuing operations to approximately 16 percent from approximately 13 to 14 percent over adjusted diluted earnings per share from continuing operations of $3.84 for the full fiscal year 2007. Reported diluted earnings per share from continuing operations for the full fiscal year 2007 were $3.36, which included 48 cents for in-process research and development charges related to the TriPath and Plasso acquisitions. Excluding these charges, adjusted diluted earnings per share from continuing operations for the full fiscal year 2007 were $3.84.

Conference Call Information

A conference call regarding BD's third fiscal quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, http://www.bd.com/investors, at 10:00 a.m. (EDT) Thursday, July 24, 2008. The conference call will be available for replay on BD's website, http://www.bd.com/investors, or at 800-642-1687 (domestic) and 706-645-9291 (international), Conference ID: 52522900, through the close of business on Thursday, July 31, 2008.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

This press release, including the section entitled "Fiscal 2008 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in thousands, except per share data)

Three Months Ended June 30,

2008 2007 % Change

REVENUES $1,867,587 $1,631,159 14.5

Cost of products sold 917,362 791,071 16.0

Selling and

administrative 440,588 412,164 6.9

Research and

development 100,071 92,993 7.6

Acquired in-process

research and

development - 7,394 NM

TOTAL OPERATING COSTS

AND EXPENSES 1,458,021 1,303,622 11.8

OPERATING INCOME 409,566 327,537 25.0

Interest income 10,956 11,938 (8.2)

Interest expense (9,017) (11,598) (22.3)

Other income, net (1,285) 1,774 NM

INCOME FROM CONTINUING

OPERATIONS BEFORE

INCOME TAXES 410,220 329,651 24.4

Income tax provision 112,811 89,182 26.5

INCOME FROM CONTINUING

OPERATIONS 297,409 240,469 23.7

(LOSS)/INCOME FROM

DISCONTINUED

OPERATIONS NET OF INCOME

TAX (BENEFIT)/PROVISION

OF $(197) AND $2,704,

RESPECTIVELY (320) 4,340 NM

NET INCOME $297,089 $244,809 21.4

EARNINGS PER SHARE

Basic:

Income from continuing

operations $1.22 $0.98 24.5

Income from

discontinued

operations $- $0.02 NM

Net income $1.22 $1.00 22.0

Diluted:

Income from continuing

operations $1.18 $0.95 24.2

Income from

discontinued

operations $- $0.02 NM

Net income (1) $1.18 $0.96 22.9

AVERAGE SHARES

OUTSTANDING

Basic 244,273 244,918

Diluted 251,648 254,128

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

(Unaudited; Amounts in thousands, except per-share data)

Three Months Ended June 30, 2007

As Plasso Excluding

Reported IPR&D (1) Item

Operating Income $327,537 $7,394 $334,931

as a % of revenues 20.1% 20.5%

Income Taxes 89,182 - 89,182

effective tax rate 27.1% 26.5%

Income from continuing

operations 240,469 7,394 247,863

as a % of revenues 14.7% 15.2%

Diluted earnings per

share

Income from continuing

operations $0.95 $0.03 $0.98

(1) Represents the acquired in-process research and development charge of

$7,394 related to the Plasso acquisition.

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in thousands, except per share data)

Nine Months Ended June 30,

2008 2007 % Change

REVENUES $5,320,279 $4,708,607 13.0

Cost of products sold 2,601,016 2,264,544 14.9

Selling and

administrative 1,277,828 1,202,879 6.2

Research and

development 287,633 259,620 10.8

Acquired in-process

research and

development - 122,133 NM

TOTAL OPERATING COSTS

AND EXPENSES 4,166,477 3,849,176 8.2

OPERATING INCOME 1,153,802 859,431 34.3

Interest income 32,489 37,138 (12.5)

Interest expense (27,455) (36,152) (24.1)

Other income, net 252 5,278 NM

INCOME FROM CONTINUING

OPERATIONS BEFORE

INCOME TAXES 1,159,088 865,695 33.9

Income tax provision 315,147 258,636 21.8

INCOME FROM CONTINUING

OPERATIONS 843,941 607,059 39.0

INCOME FROM DISCONTINUED

OPERATIONS NET OF INCOME

TAX PROVISION OF $538

AND $14,066, RESPECTIVELY 880 23,162 NM

NET INCOME $844,821 $630,221 34.1

EARNINGS PER SHARE

Basic:

Income from continuing

operations $3.45 $2.47 39.7

Income from

discontinued

operations $- $0.09 NM

Net income (1) $3.46 $2.57 34.6

Diluted:

Income from continuing

operations $3.34 $2.38 40.3

Income from

discontinued

operations $- $0.09 NM

Net income $3.34 $2.47 35.2

AVERAGE SHARES OUTSTANDING

Basic 244,478 245,296

Diluted 252,944 255,129

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

(Unaudited; Amounts in thousands, except per share data)

Nine Months Ended June 30, 2007

As TriPath Plasso Excluding

Reported IPR&D (1) IPR&D (1) Items

Operating Income $859,431 $114,739 $7,394 981,564

as a % of revenues 18.3% 20.8%

Income taxes 258,636 - - 258,636

effective tax rate 29.9% 26.2%

Income from continuing

operations 607,059 114,739 7,394 729,192

as a % of revenues 12.9% 15.5%

Diluted earnings per

share

Income from continuing

operations $2.38 $0.45 $0.03 $2.86

(1) Represents the acquired in-process research and development charges of

$114,739 and $7,394 related to the TriPath and Plasso acquisitions,

respectively.

Fiscal Year 2007

As Excluding

Reported IPR&D (2) Items

Diluted earnings per share

Income from continuing

operations $3.36 $0.48 $3.84

(2) Represents the acquired in-process research and development charges

related to the TriPath and Plasso acquisitions.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY SEGMENT AND GEOGRAPHIC AREA

(Unaudited; Amounts in thousands)

Three Months Ended June 30,

2008 2007 % Change

BD MEDICAL

United States $401,918 $385,546 4.2

International 614,478 496,440 23.8

TOTAL $1,016,396 $881,986 15.2

BD DIAGNOSTICS

United States $280,118 $272,946 2.6

International 273,304 218,579 25.0

TOTAL $553,422 $491,525 12.6

BD BIOSCIENCES

United States $116,239 $109,593 6.1

International 181,530 14
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Gerbig Engineering Announces Availability of Cleanroom Utility Panel
2. The Palomino Group Announces Launch of Meeting Support Services Business Unit
3. Misys Announces Preliminary Results for the Year Ended 31 May 2008
4. Cardiome Announces Preferred Share Financing
5. Mercy Health Plans Announces New Name for Their Medicare Advantage Plans: Mercy Medicare Advantage
6. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
7. The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates
8. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
9. Fitness Equipment Retailer Fitness 4 Home Superstore Announces New Scottsdale Location
10. Fidelity National Financial, Inc. Announces Opening of Fidelity National Title de Mexico S.A. de C.V.
11. CIHR announces $4.4 million to improve mental health of Canadians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... San Francisco, CA (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, ... (TSF) will take on steep California terrain at the first Team Semper Fi Mountain Bike ... Joining them will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share ...
(Date:5/5/2016)... ... 05, 2016 , ... LELO has discovered many people are insecure ... out via email, social media and on the Volonté blog seeking advice about how ... masturbate ‘normal’ or ‘correct’?” , While some methods are more common than others, there ...
(Date:5/5/2016)... MA (PRWEB) , ... May 05, 2016 , ... ... among workers’ compensation laws in all U.S. states and certain Canadian provinces is ... and the Workers Compensation Research Institute (WCRI). , The report, Workers’ ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Long Island’s fastest ... merger of noted Long Island eye surgeon, Kathleen Van Valkenburg, MD as part of ... to Jeffrey Martin, MD, medical director and managing partner of North Shore Eye Care. ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... resources for veterinary professionals across the United States. The whole food nutrient solutions ... their patients and giving dog, cat and horse owners’ peace of mind. With ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... Calif. , May 5, 2016  Diagnostic ... a decade due to concerns that these tests ... the approach to imaging, as well as the ... new era of medical peripherals that help health care providers ...   Ampronix  advanced medical imaging is a renowned authorized ...
(Date:5/5/2016)... May 5, 2016 Research and Markets has ... in Top 5 EU Markets"  report to their offering.  ,     ... provides information on the current Positron Emission Tomography (PET) scanner ... (T5 EU), which includes France , ... Spain and the United Kingdom ...
(Date:5/5/2016)... , May 5, 2016 /PRNewswire/ ... announced the addition of the  "Europe ... - 2016"  report to their offering.  ... ) , ,The latest research ... Highlights - 2016, provides comprehensive insights ...
Breaking Medicine Technology: